Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne?Launches Simple?Plex?Ultra-Sensitive?Assays on Ella?Platform to Enable?Femtogram-Level?Detection of Neurological Biomarkers
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
